Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, Bipolar Disorder, or Depressive Disorders.~* Have a clinical diagnosis of neuroleptic-induced TD.~* Have moderate or severe TD.~* If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or bipolar disorder, or depressive disorders, be on stable doses.~Exclusion Criteria:~* Have an active, clinically significant unstable medical condition in screening period.~* Have a significant risk of suicidal or violent behavior.~* Have a known history of long QT syndrome or cardiac tachy-arrhythmia.~* Are currently pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MT-5199 40 mg (Double-Blind Placebo-Controlled Period) (Type: EXPERIMENTAL): MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
- MT-5199 80 mg (Double-Blind Placebo-Controlled Period) (Type: EXPERIMENTAL): Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
- Placebo (Double-Blind Placebo-Controlled Period) (Type: EXPERIMENTAL): Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
- MT-5199 40 mg (Double-Blind Extension Period) (Type: EXPERIMENTAL): At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
- MT-5199 80 mg (Double-Blind Extension Period) (Type: EXPERIMENTAL): At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.

Based on this trial design, predict the completion outcome and termination type (if applicable).